UNION therapeutics announces two peer-reviewed publications of preclinical and clinical Phase 2a data on orismilast
· New insights into the pharmacological properties of orismilast and Phase 2a data published in peer-reviewed journal JEADV · Data supports orismilast’s potential as a first-in-class or best-in-class treatment for a range of immunological diseases · UNION is currently developing orismilast modified release (MR) tablet as a safe oral treatment of psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS) Hellerup, Denmark, 22 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on